Skip to main content

Table 2 Motor nerve conduction tests in patients with HD, ALS or CSA

From: Electrophysiological differences between Hirayama disease, amyotrophic lateral sclerosis and cervical spondylotic amyotrophy

 

Median nerve

Ulnar nerve

U/M ratio

 

Amplitude (mV)

CV (m/s)

Amplitude (mV)

CV (m/s)

Amplitude

CV

HD

Affected limb

8.2 ± 3.9&

59.3 ± 4.3

3.2 ± 2.6&

60.3 ± 5.5

0.55 ± 0.41&

1.02 ± 0.11

 

Healthy limb

10.3 ± 2.4

60.2 ± 3.5

9.0 ± 1.9

59.3 ± 4.2

0.98 ± 0.22

1.03 ± 0.11

ALS

Affected limb

2.3 ± 2.2*&

55.5 ± 4.5*&

4.8 ± 3.5*&

56.6 ± 6.0*&

2.28 ± 1.25*&

1.10 ± 0.18

 

Healthy limb

7.9 ± 2.4#

54.8 ± 3.9*

8.4 ± 2.4

55.2 ± 4.2#

1.12 ± 0.32

1.04 ± 0.14

CSA

Affected limb

4.5 ± 3.1*&

57.4 ± 5.2

4.9 ± 3.1*&

55.1 ± 4.1*&

1.21 ± 0.53*

0.95 ± 0.13

 

Healthy limb

8.2 ± 2.0#

57.2 ± 3.2*

7.8 ± 1.8#

55.2 ± 4.3*

0.97 ± 0.34

0.93 ± 0.17

Normal controls

 

9.0 ± 1.5

59.8 ± 3.1

9.5 ± 1.8

60.2 ± 3.2

1.15 ± 0.23

1.01 ± 0.12

  1. *P < 0.0001, the affected (healthy) limbs of patients with ALS or CSA vs. the affected (healthy) limbs of patients with HD.
  2. #P < 0.001, the affected (healthy) limbs of patients with ALS or CSA vs. the affected (healthy) limbs of patients with HD.
  3. &P < 0.0001, the affected limbs of patients with HD, ALS or CSA patients vs. the limbs of normal controls.
  4. HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic amyotrophy; CV, conduction velocities; U/M, ulnar/median.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us